1. The supplementation of L-carnitine in critically ill patients with sepsis: a systematic review and meta-analysis of randomized controlled trials.
- Author
-
Meng C, Ma Y, Fu N, Li J, Sun B, Li Z, Wang Q, and Liu P
- Subjects
- Humans, Randomized Controlled Trials as Topic, Carnitine administration & dosage, Critical Illness mortality, Critical Illness therapy, Dietary Supplements, Sepsis diet therapy, Sepsis mortality
- Abstract
Objectives: The evidence suggests that L-carnitine may reduce mortality in critically ill patients with sepsis. However, the conclusions of different studies are inconsistent. A meta-analysis was conducted to evaluate the effect of L-carnitine compliance on mortality in patients with sepsis., Methods: A search of the PubMed, Embase, and Cochrane Library databases was conducted on 1 June 2024. The risk ratio (RR) was pooled with a 95% confidence interval (CI) for dichotomous data. The publications were subjected to a review in accordance with the guidelines set forth in the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). This study has been registered with INPLASY (number INPLASY202460086)., Results: A total of 356 patients were included in four randomized controlled trials. The results indicated that L-carnitine supplementation was not associated with 28-day mortality in sepsis patients (RR: 0.65; 95% CI 0.33-1.28; I
2 = 70%; P = 0.21). And there was no significant effect on 12-month mortality (RR: 0.72; 95% CI 0.47-1.11; I2 = 0%; P = 0.14) compared to placebo., Conclusions: The use of L-carnitine was not found to be significantly correlated with 28-day or 12-month mortality in patients with sepsis., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF